Cocaine vaccine enters human testing

NCT ID NCT02455479

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a vaccine called dAd5GNE in 150 people who are dependent on cocaine. The vaccine is designed to train the immune system to attack cocaine, preventing it from reaching the brain and causing a high. The main goal is to check if the vaccine is safe, while also measuring whether it reduces cocaine use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dAd5GNE vaccine

What this could lead to

If it works, this vaccine could help people with cocaine dependence by reducing cravings and preventing relapse.

What could go wrong

This is a very early phase 1 trial focused on safety, so it may not prove effective. The vaccine may not produce strong enough immunity to block cocaine's effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COCAINE DEPENDENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cocaine dependence Cocaine-Related Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • WCMC Department of Genetic Medicine

    RECRUITING

    New York, New York, 10021, United States

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••